Another US Food and Drug Administration-approved CAR-T cell-based therapy that targets B cell tumor antigens is B cell maturation antigen (BCMA)-specific CAR-T cells, which are approved for treating multiple myeloma. The gene discussed is TNFRSF17; the disease is neoplasm.